SLC5A2 and type 2 diabetes mellitus: The subgroup analyses in this study furtherrevealed that SGLT-2 inhibitors are the optimal choice for increasing LVEF in HFpatients with increased or decreased ejection fraction or in HF patients withcomorbid T2DM.